THC Mechanism of Action on Cannabinoid Receptors
THC functions as a partial agonist at both CB1 and CB2 cannabinoid receptors, with CB1 receptor activation primarily responsible for its psychoactive and therapeutic effects. 1
Receptor Binding Profile
THC acts as a partial agonist at both receptor subtypes:
CB1 receptors: THC binds to and partially activates CB1 receptors, which are densely distributed throughout the central nervous system, including the cerebral cortex, hippocampus, basal ganglia, cerebellum, and peripheral nervous system 2
CB2 receptors: THC also functions as a partial agonist at CB2 receptors, which are primarily located on immune cells (immunocytes and macrophages), epithelial cells, and to a lesser extent in neurons including sensory neurons 3
Clinical Significance of Dual Receptor Activity
The CB1 receptor mediates the majority of THC's clinically relevant effects:
CB1 activation is responsible for THC's euphorigenic (psychoactive) effects, as well as its influence on anxiety, depression, gastrointestinal secretions, emesis, and appetite control 3
CB1 receptors are found in virtually all CNS tissues and represent potential targets for pharmacological intervention in pain pathways 1
The dorsal vagal complex contains dense CB1 receptor distribution, which is critically important in neurocircuits controlling emesis 3
CB2 receptor activation contributes to anti-inflammatory and immunomodulatory effects:
CB2 receptors mediate effects on inflammation and nociception through their location on inflammatory cells and sensory neurons 3
CB2 activation may play a role in modulating immune responses, though this is less directly related to THC's primary psychoactive properties 2
Partial Agonist Properties
The partial agonist nature of THC at both receptors has important clinical implications:
As a partial agonist, THC's effects are strongly influenced by cannabinoid receptor expression levels, signaling efficiency, and ongoing endogenous cannabinoid release 1
This partial agonism may explain THC's relatively favorable safety profile compared to full agonists, as maximal receptor activation is limited even at high doses 4
Recent structural studies demonstrate that THC and its analogs create differential spatiotemporal interactions with CB1 receptors that govern potency, efficacy, signaling bias, and binding kinetics 5, 6
Additional Receptor Interactions
Beyond CB1 and CB2, THC binds to other receptors that contribute to its overall pharmacological profile:
THC interacts with transient receptor potential vanilloid type 1 (TRPV1) channels, which are considered important in conditions like cannabinoid hyperemesis syndrome due to effects on the vagus nerve and gut functions 3
Some evidence suggests THC may interact with GPR55 receptors, though the clinical significance remains under investigation 7